Assessing the role of Anti-Müllerian hormone in women's reproductive health
Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
This study is testing if measuring a hormone called Anti-Müllerian hormone (AMH) can help women with conditions like polycystic ovarian syndrome and premature ovarian insufficiency, and improve their chances of success with fertility treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 10 Years to 44 Years |
| Sex | Female |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05858307 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the association of serum Anti-Müllerian hormone (AMH) levels with conditions such as polycystic ovarian syndrome (PCOS) and premature ovarian insufficiency (POI), as well as its predictive value in assisted reproductive technology (ART) outcomes. The study aims to determine the utility of AMH in diagnosing PCOS, managing POI, and optimizing gonadotropin regimens for ovarian stimulation in ART. By analyzing AMH levels alongside other reproductive markers, the research seeks to enhance understanding of ovarian function and improve reproductive outcomes for women undergoing ART.
Who should consider this trial
Good fit: Ideal candidates include women attending clinics for the management of PCOS and POI, as well as those seeking ART treatment.
Not a fit: Patients outside the age range of 10 to 45 years or those with conditions affecting hormone secretion may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable biomarker for diagnosing and managing reproductive health issues in women, potentially improving fertility outcomes.
How similar studies have performed: Previous studies have shown promising results in using AMH as a marker for reproductive health, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI * Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment Exclusion Criteria: * Women with age \<10 or ≥45 * Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Pui Wah Jacqueline Chung — Chinese University of Hong Kong
- Study coordinator: Wing Iu Li
- Email: wingiuli@cuhk.edu.hk
- Phone: +852 35051764
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.